Clarivate identifies thirteen potential blockbuster drugs and gamechangers in annual drugs to watch report

Therapeutic advancements for sickle cell disease, rsv, breast cancer, crohn's and other ailments poised to advance patient health despite urgent challenges facing life science companies london , jan. 8, 2024 /prnewswire/ -- clarivate plc (nyse:clvt), a global leader in connecting people and organizations to intelligence they can trust to transform their world, today announced the release of its annual drugs to watch™ report. the report provides in-depth predictive analysis of drugs with the potential for standout commercial and/or clinical success.
CLVT Ratings Summary
CLVT Quant Ranking